Perspective of Botox for treatment of male lower urinary tract symptoms

Current Opinion in Urology

Volumn 19, Issue 1, 2009, Pages 20-25

  Ilie, Cristian P ^a   Chancellor, Michael B ^b  

^a Central Military Hospital Bucharest   (Romania)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Benign prostatic hyperplasia; Botulinum toxin; Prostate

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; NORADRENALIN;

ACETYLCHOLINE RELEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; DYSURIA; EPIDIDYMITIS; HEMATURIA; HUMAN; LOWER URINARY TRACT SYMPTOM; NICK END LABELING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOOTH MUSCLE TONE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BOTULINUM TOXIN TYPE A; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; NEUROMUSCULAR AGENTS; PROSTATE; PROSTATIC HYPERPLASIA; RATS; URINARY TRACT;

EID: 58149269312     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328316c33f     Document Type: Review

References (52)

1. Roehrborn CG, Bartsch G, Kirby R, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58:642-650.
2. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population based survey of urinary symptom. J Urol 1993; 150:85-89.
3. De la Rosette JJMCH, Alivizatos G, Madersbacher S, et al. Guidelines on benign prostatic hyperplasia In: Aus G, Hanus T, Irani J, et al., editors. European Association of Urology guidelines, 2008 ed. Amhem: EAU Guidelines Office; 2008. pp. 1-7.
4. Arrighi HM, Metter EJ, Guess HA, et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy, the Baltimore Longitudinal Study of Aging. Urology 1991; 35 (Suppl):4-8.
5. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for treatment of human disease. Perspect Biol Med 1997; 40:317-327.
6. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J Urol 2004; 171:2128-2137.
7. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87:1044-1049.
8. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139:919-922.
9. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164:692-697.
10. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006; 13 (Suppl 4):1-9.
11. Gury C. Pharmacological and medico-economic considerations. In: Ranoux D, Gury C, editors. Practical handbook on botulinum toxin, 2007 ed. Marseille: Solal Editeurs; 2007. pp. 13-35.
12. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990; 17:461-475.
13. Moore AP. General and clinical aspects of treatment with botulinum toxin. In: Moore AP, editor. Botulinum toxin treatment. Oxford: Blackwell Science; 1995. pp. 28-53.
14. Shaari CM, Sanders I, Wu BL, Biller HF. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 1995; 112:566-571.
15. Rohrbach S, Olthoff A, Laskawim R, et al. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Rhinol Laryngol 2001; 110:1045-1050.
16. Chuang YC, Chancellor MB. The application of botulinum toxin in the prostate. J Urol 2006; 176:2375-2382.
17. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001; 248:3-10.
18. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002; 18:S177-S181.
19. Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004; 172:1529-1532.
20. Khera M, Somogyi GT, Kiss S, et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45:987-993.
21. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin type A reduces formalin-induced pain. Pain 2004; 107: 125-133.
22. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175:2341-2344.
23. Jabber B, Maher N, Difazio MP. Botulinum toxin a improved burning pain and alloying in two patients with spinal cord pathology. Pain Med 2003; 4:206-210.
24. 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174:977-982.
25. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169:1896-1900.
26. Choo MS. Investigating botulinum toxin A on the functional proprieties of the prostate. Eur Urol 2007; 52:324-325.
27. Horsfall DJ, Mayne K, Ricciardelli C. Age-related changes in guinea pig prostatic stroma. Lab Invest 1994; 70:753-763.
28. Lepor H, Zhang W, Kobayashi S, et al. A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. J Pharmacol Exp Ther 1994; 270:722-727.
29. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox induced prostatic involution. Prostate 1998; 37:44-50.
30. Chuang YC, Huang CC, Kang HY, et al. Novel action of botulinum toxin on the stromal and epithelial components of prostate gland. J Urol 2006; 173:1158-1163.
31. Ventura S, Pennefather J, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002; 94:93-112.
32. Chuang YC, Yoshimura N, Wu M, et al. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. Eur Urol 2007; 51:1119-1127. This study reports a novel model for nonbacterial prostatitis and BTX-A anti-inflammatory and analgesic effects, supporting clinical evaluation not only in prostatitis but also in BPH-related inflammatory changes.
33. Chuang YC, Yoshimura N, Huang CC, et al. Intraprostatic botulinum toxin A injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J Urol 2008; 180:742-748. This study shows that BTX-A pretreatment inhibits capsaicin-induced cyclooxygenase-2 expression and inhibits prostatic pain and inflammation with clinical implications in prostatitis and BPH.
34. Chuang YC, Tu CH, Huang CC, et al. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 2006; 6:12.
35. Lin AT, Yang AH, Chen KK. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007; 52:582-589. The authors demonstrate that injecting BTX-A into the dog prostate reduces contractile function. This contributes to the understanding of BTX-A action on the dynamic component of LUTS.
36. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology 2007; 51:1202-1216. This review covers recent developments in the role of chronic inflammation in the pathogenesis and progression of BPH.
37. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003; 169:1520-1525.
38. Thomas CA, Guercini F, Chuang YC, Chancellor MB. Botulinum-A toxin: an exciting new treatment option for prostatic disease. Int J Clin Pract 2006; 60:33-37.
39. Witte LPW, Chapple CR, De la Rosette JJMCH, Michael MC. Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol 2008; 54:326-334. The authors review the cholinergic innervation in the human prostate. This paper may contribute to the understanding of BTX-A mechanism of action.
40. Ravindranath N, Wion D, Brachet P, et al. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001; 22:432-443.
41. Mariness D, Patel R, Walden PD. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 2003; 54:230-237.
42. Chuang YC, Giannantoni A, Chancellor MB. The potential and promise of using botulinum toxin in the prostate gland. BJU Int 2006; 98:28-32.
43. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62:259-264.
44. Chuang YC, Chiang PH, Huang CC, et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005; 66:775-779.
45. Chuang YC, Chiang PH, Yoshimura N, et al. Sustained beneficial effects of intraprostatic botulinum toxin type A injection on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006; 98:1033-1037.
46. Kuo HC. Prostate botulinum toxin A injection: an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65:670-674.
47. Park DS, Cho TW, Lee YK, et al. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006; 47:706-714.
48. Silva J, Silva C, Saraiva L, et al. Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement: effect on prostate volume and micturition resumption. Eur Urol 2008; 53:153-159. This is the first paper addressing the intraprostatic BTX-A in patients presenting with chronic indwelling catheter.
49. Guercini F, Giannantoni A, Bard RL, et al. Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia a multicenter feasibility study [abstract #1387]. J Urol 2005; 173 (4 Suppl):376.
50. Larson TR, Scottsdale AZ, Huidobro C, Acevedo C. Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIS for accurate changes in size of the prostate [abstract #1386]. J Urol 2005; 173 (4 Suppl):376.
51. Kuo HC. Therapeutic effects of botulinum toxin A on large benign prostatic hyperplasia with persistent lower urinary tract symptoms and suboptimal treatment outcome of combination medical therapy: clinical and histological investigation of effects. J Urol 2007; 177 (Suppl):609-610.
52. Oeconomou A, Madersbacher H, Kiss G, et al. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 2008 [Epub ahead of print]. This is an up-to-date review of the literature regarding the use of BTX-A for LUTS/BPH.